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Introduction: Published data on the association between XPD Lys751Gln
and Asp312Asn gene polymorphism and lung cancer risk are inconclusive.
Methods: To derive a more precise estimation of the relationship, a
meta-analysis was performed.
Results: A total of 22 studies including 15,507 subjects for XPD
Lys751Gln genotype and 13,198 subjects for XPD Asp312Asn ge-
notype were examined. For XPD Lys751Gln genotype, significantly
increased lung cancer risk was associated with two variant geno-
types (CC versus AA: odds ratio [OR]  1.26, 95% confidence
interval [CI]  1.12–1.42, p  0.473 for heterogeneity; C allele
carriers versus AA: OR 1.18, 95% CI 1.08–1.36, p 0.732 for
heterogeneity). When stratified by ethnicity, significantly increased
risks were found among Caucasians but not in Asians. For XPD
Asp312Asn genotype, significantly increased lung cancer risk was
associated with two variant genotypes (AA versus GG: OR  1.24,
95% CI  1.09–1.42, p  0.104 for heterogeneity; the A allele
carriers versus GG: OR 1.35, 95% CI 1.13–1.57, p 0.219 for
heterogeneity). When stratified analysis by ethnicity, significantly
increased risks were found among Asians but not in Caucasians. In
the subgroup analyses by smoking status, there were no significant
associations among the nonsmoker subgroup; however, significantly
increased lung cancer risks were found in the smoking group.
Conclusion: This meta-analysis suggests that the XPD Lys751Gln
and Asp312Asn gene polymorphisms are associated with lung cancer
risk, the C allele of XPD Lys751Gln genotype is an increased risk
factor for developing lung cancer among Caucasians and in smokers,
and the A allele of XPD 312 genotype is also an increased risk factor
among Asians and in smokers.
Key Words: ERCC2/XPD, Polymorphism, Lung cancer, Suscepti-
bility, Meta-analysis.
(J Thorac Oncol. 2010;5: 1337–1345)
Lung cancer remains the deadliest cancer worldwide despiteimprovements in diagnostic and therapeutic techniques.1
Incidence has yet to peak in many parts of the world,
particularly in China where lung cancer and tobacco smoking
has become a major public health challenge.2 The mechanism
of lung carcinogenesis is still not fully understood. Smoking
status has been well established as the single most important
factor in causing lung cancer; however, host factors including
genetic polymorphisms have been recently implicated in
contributing to tumorigenesis of lung cancer.3
In recent years, several common low-penetrant genes
have been identified as potential lung cancer susceptibility
genes. Polymorphisms of the genes belonging to the base
excision repair pathway, such as x-ray repair cross-comple-
menting group 1 (XRCC1), and the nucleotide excision repair
(NER) pathway, such as excision repair cross-complementing
group 1 (ERCC1) and xeroderma pigmentosum group D
(ERCC2/XPD), have been extensively studied. ERCC2/XPD
exhibits dual functionality in the cell because it is involved in
NER and cell cycle regulation through Cdk-activating ki-
nase.4 Several XPD polymorphisms (located in codons 156,
312, 711, and 751) were recently identified in the coding
regions with relatively high allele frequencies (25%).5,6
Two particular XPD polymorphisms (Lys751Gln and
Asp312Asn) have been the focus of investigations into their
relationship with phenotypic endpoints relevant to lung car-
cinogenesis. The predominant homozygous allele, the het-
erozygous allele, and the homozygous rare allele of the
Lys751Gln gene polymorphism are named accordingly: the
homozygous wild-type genotype (AA or Lys/Lys); the het-
erozygote (AC or Lys/Gln); and the rare homozygote (CC or
Gln/Gln). For the Asp312Asn gene polymorphism, the variant
genotype was the homozygous wild-type genotype (GG or
Asp/Asp), the heterozygote (AG or Asp/Asn), and the rare
homozygote (AA or Asn/Asn).
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A number of studies reported the role of XPD
Lys751Gln and Asp312Asn polymorphisms in lung cancer
risk, but the results were largely inconclusive. This dichot-
omy could be the result of a possible small effect of the
polymorphism on lung cancer risk or the relatively small
sample size in each published studies. Hu et al.7 found an
increase in cancer risk for the XPD 751 C, 312 A alleles,
XPD 751 CC, and 312 AA genotypes through a meta-analysis
of data from nine case–control lung cancer populations.
However, in Benhamou and Sarasin’s meta-analysis using
seven studies,8 no statistically significant associations were
found. When these meta-analyses were performed, the pooled
sample size was relatively small. Since then, several addi-
tional studies with large cohort populations have been re-
ported. Furthermore, the previous studies lacked proper con-
trols for the potential confounding effect of smoking, the
main risk determinant for lung cancer. Simple differences in
cohort populations and study design may also contribute to
the disparate findings. Therefore, we performed a large and
comprehensive meta-analysis including the most recent pub-
lished studies to derive a more precise estimation of the
phenotype association.
MATERIALS AND METHODS
Publication Search
The electronic databases PubMed, Embase, Web of
Science, and China National Knowledge Infrastructure were
searched for studies to include in this meta-analysis by using
the terms “ERCC2,” “XPD,” “polymorphism,” and “lung
cancer.” An upper date limit of September 30, 2009, was
applied; no lower date limit was defined. The search was
carried out without restriction on language but was focused
on studies that had been conducted on human subjects. We
also reviewed the Cochrane Library for relevant articles. The
reference lists of reviews and retrieved articles were also
manually reviewed. Only published studies with full-text
articles were included. When more than one of the same
patient population was included in several publications, only
the most recent or complete study was used in this meta-
analysis.
Inclusion Criteria
Studies were required to meet the following criteria for
inclusion: (1) evaluated the ERCC2/XPD gene polymorphism
and lung cancer risk; (2) case–control studies; (3) supplied
the number of individual genotypes for ERCC2/XPD
Lys751Gln and Asp312Asn gene in lung cancer cases and
controls, respectively; and (4) the distribution of genotypes
among controls were in Hardy-Weinberg equilibrium.
Data Extraction
Information was carefully extracted from all eligible
publications independently by two authors according to the
inclusion criteria listed above. Disagreement was resolved by
discussion between the two authors. The following data were
collected from each study: first author’s surname; year of
publication; ethnicity; characteristics of matching criteria in
controls; total numbers of cases and controls; and numbers of
cases and controls with the ERCC2/XPD Lys751Gln and
Asp312Asn genotypes, respectively. If data from any of the
above categories were not reported in the primary study,
items were treated as “not applicable.” We did not contact the
author of the primary study to request missing or additional
information. Ethnicity was categorized as Asian, Caucasian,
and mixed population. We also abstracted the information
regarding smoking status from available studies. Subjects
were divided between a smokers group (including former and
current smokers) or a nonsmokers group. No minimum num-
ber of patients to include from a study was applied to our
meta-analysis.
Statistical Analysis
Odds ratio (OR) with 95% confidence interval (CI) was
used to assess the strength of association between the
ERCC2/XPD Lys751Gln and Asp312Asn gene polymor-
phisms and lung cancer risk. The pooled ORs for the risk
associated with the genotypes of the rare homozygote and the
allele carriers (AC  CC for XPD Lys751Gln genotype and
GA  AA for XPD Asp312Asn genotype) with the homozy-
gous wild-type genotype were calculated. Subgroup analyses
were carried out according to ethnicity and smoking status.
Heterogeneity assumption was verified by the 2-based Q
test.9 A p value greater than 0.10 for the Q test indicates a
lack of heterogeneity among studies, so the pooled OR
estimate of each study was calculated by the fixed-effects
model (the Mantel-Haenszel method).10 Otherwise, the ran-
dom-effects model (the DerSimonian and Laird method) was
used.11 One-way sensitivity analyses were performed to as-
sess the stability of the results, namely, a single study in the
meta-analysis was deleted each time to reflect the influence of
the individual dataset on the pooled OR.12 An estimate of
potential publication bias was carried out using funnel plot-
ting in which the standard error of log (OR) of each study was
plotted against its log (OR). An asymmetric plot suggested a
possible publication bias. Funnel plot asymmetry was as-
sessed by the method of Egger’s linear regression test, a
well-established linear regression approach to measure the
funnel plot asymmetry on the natural logarithm scale of the
OR. The significance of the intercept was determined by the t test
suggested by Egger (p  0.05 was considered representative
of statistically significant publication bias).13 All the calcula-
tions were performed using STATA version 10.0 (Stata
Corporation, College Station, TX).
RESULTS
Study Characteristics
A total of 22 publications met the inclusion crite-
ria.14–35 For XPD Lys751Gln genotype, a total of 21 studies
involving 6824 lung cancer cases and 8683 controls were
ultimately analyzed. A study by David-Beabes et al.15 sorted
the data among Caucasians and African Americans; there-
fore, each group in the study was considered separately for
pooling subgroup analyses. For the ERCC2/XPD Asp312Asn
genotype, a total of 17 studies involving 5820 lung cancer
cases and 7378 controls were ultimately analyzed. Tables
1and 2 present the main characteristics of these studies.
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Among the 22 publications, 19 were published in English and
three were in Chinese. The sample sizes ranged from 190 to
2332. Almost all the cases were histologically confirmed.
Controls were mainly healthy populations and matched for
age, ethnicity, and/or smoking status. There were nine groups
of Asians, 11 groups of Caucasians, and two of mixed
population for XPD Lys751Gln genotype; for the ERCC2/
XPD Asp312Asn genotype, there were six groups of Asians,
10 groups of Caucasians, and one of mixed population. Nine
studies contained enough information for subgroup analyses
by smoking status. Hardy-Weinberg equilibrium had been
tested for all polymorphisms in the control subjects, and all
were in Hardy-Weinberg equilibrium.
Meta-Analysis Results
Table 3 lists the main results of this meta-analysis. For
the XPD Lys751Gln genotype, overall, significantly increased
lung cancer risk was associated with two variant genotypes
when all studies were pooled into the meta-analysis (CC
versus AA: OR  1.26, 95% CI  1.12–1.42, p  0.473 for
heterogeneity; C allele carriers versus AA: OR  1.18, 95%
CI  1.08–1.36, p  0.732 for heterogeneity) (Figure 1).
When stratified by ethnicity, significantly increased risks
were found among Caucasians for both the homozygote
CC versus AA (OR  1.35, 95% CI  1.17–1.56; p 
0.923 for heterogeneity) and the C allele carriers versus
AA (OR  1.32, 95% CI  1.12–1.62; p  0.358 for
heterogeneity). Among Asians, no significant association
was found in homozygote CC versus AA (OR  1.14; 95%
CI  0.92–1.43; p  0.194 for heterogeneity) or for the C
allele carriers versus AA (OR  1.27; 95% CI  0.86–
1.75; p  0.278 for heterogeneity). There were only two
studies involving mixed populations and no significant
associations were found (Table 3).
For the XPD Asp312Asn genotype, overall, signifi-
cantly increased lung cancer risk was associated with two
variant genotypes when all studies were pooled into the
meta-analysis (AA versus GG: OR  1.24, 95% CI 
1.09–1.42, p  0.104 for heterogeneity; A allele carriers
versus GG: OR  1.35, 95% CI  1.13–1.57, p  0.219 for
heterogeneity) (Figure 2). When stratified by ethnicity, sig-
nificantly increased risks were found among Asians for both
the homozygote AA versus GG (OR  1.62, 95% CI 
1.26–2.09; p  0.046 for heterogeneity) and the A allele
carriers versus GG (OR  1.84, 95% CI  1.31–2.27; p 
0.238 for heterogeneity). Among Caucasians, no significant
association was found with homozygote AA versus GG
(OR  1.14; 95% CI  0.97–1.33; p  0.490 for heteroge-
neity) or the A allele carriers versus GG (OR  1.04; 95%
CI  0.83–1.52; p  0.374 for heterogeneity). There was
only one study involving mixed populations and no signifi-
cant associations were found (Table 3).
In the subgroup analyses divided among smoking
status, there were no significant associations among the
nonsmoker subgroup; however, the smoking group re-
vealed significantly increased lung cancer risks for both
the XPD Lys751Gln genotype and XPD Asp312Asn geno-
type (Table 3).
Sensitivity Analyses
A single study that had been used in the meta-analysis
was deleted each time to reflect the influence of the individual
dataset on the pooled ORs. None of the corresponding pooled
ORs were materially altered (data not shown).
Publication Bias
Begg’s funnel plot and Egger’s test were performed to
access the publication bias of the literature used in the
meta-analysis. The shapes of the funnel plots did not reveal
any evidence of obvious asymmetry (Figures 3 and 4). Ac-
cordingly, the Egger’s test was used to provide statistical
evidence of the observed funnel plot symmetry. The results
still did not suggest any evidence of publication bias (p 
0.369 for CC versus AA of XPD Lys751Gln genotype; p 
0.522 for AA versus GG of XPD Asp312Asn genotype).
DISCUSSION
This meta-analysis, including 15,507 subjects from 21
published case–control studies for examining the XPD
Lys751Gln genotype and 13,198 subjects from 17 case–
control studies for XPD Asp312Asn genotype, explored the
association between the XPD Lys751Gln and Asp312Asn
TABLE 3. Summary ORs for Various Contrasts of ERCC2/XPD 751and 312 Gene Polymorphisms in This Meta-Analysis
Item
XPD 751 Genotype XPD 312 Genotype
Contrast Studies OR (95% CI), Ph Contrast Studies OR (95% CI), Ph
Total CC vs. AA 22 1.26 (1.12–1.42), 0.473 AA vs. GG 17 1.24 (1.09–1.42), 0.104
(CCAC) vs. AA 1.18 (1.08–1.36), 0.732 (AAAG) vs. GG 1.35 (1.13–1.57), 0.219
Asian CC vs. AA 9 1.14 (0.92–1.43), 0.194 AA vs. GG 6 1.62 (1.26–2.09), 0.046
(CCAC) vs. AA 1.27 (0.86–1.75), 0.278 (AAAG) vs. GG 1.84 (1.31–2.27), 0.238
Caucasian CC vs. AA 11 1.35 (1.17–1.56), 0.923 AA vs. GG 10 1.14 (0.97–1.33), 0.490
(CCAC) vs. AA 1.32 (1.12–1.62), 0.358 (AAAG) vs. GG 1.04 (0.83–1.52), 0.374
No smoking CC vs. AA 7 1.78 (0.56–2.96), 0.026 CC vs. AA 9 1.38 (0.78–2.19), 0.039
(CCAC) vs. AA 2.38 (0.67–3.75), 0.251 (CCAC) vs. AA 1.47 (0.93–1.93), 0.217
Smoking CC vs. AA 7 1.82 (1.28–2.67), 0.278 CC vs. AA 9 1.48 (1.23–1.79), 0.276
(CCAC) vs. AA 1.89 (1.19–2.67), 0.278 (CCAC) vs. AA 1.56 (1.31–1.87), 0.528
Ph, p value of Q test for heterogeneity test; OR, odds ratio; CI, confidence interval.
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gene polymorphisms and lung cancer risk. The results indi-
cated that XPD 751 C allele and XPD 312 A allele are all the
low-penetrant risk factors for developing lung cancer identi-
fied to date. The results support the hypothesis that the
polymorphisms of the DNA repair gene XPD which is known
to be involved in the NER pathway may play a certain role in
the development of lung cancer. Although the exact molec-
ular mechanisms underlying these XPD polymorphisms and
their affect on cancer risk remain to be elucidated, the
published studies on the structure and functions of the XPD
gene and their genetic variants could provide valuable in-
sight. It has been proven that the XPD protein takes part in
the unwinding of DNA and forms a complex with the basal
transcription factor transcription factor II H during transcrip-
tion-coupled repair.36 Mutations in the XPD gene cause a
severe but variable depression of NER, as verified by differ-
ent assay systems.37 Recently, Hou et al.38 and Qiao et al.39
reported that the two common variant alleles (located in
codons 751 and 312) of the XPD gene might lead to reduced
repair of aromatic DNA adducts, and promotion of tumor
formation.
When stratified according to ethnicity, different results
were found between Asians and Caucasians for the XPD
Lys751Gln or the Asp312Asn genotype. For the XPD
Lys751Gln genotype, significantly increased risks were iden-
tified among Caucasians for both the homozygote CC versus
AA and the C allele carriers versus AA. Among Asians,
however, no significant association was found in homozygote
CC versus AA or the C allele carriers versus AA. For the
Asp312Asn genotype, the increased risks were apparent with
both the homozygote CC versus AA and the C allele carriers
versus AA among Asians; however, the associations were not
found among Caucasians. These findings indicated that poly-
morphisms of XPD may be important in regards to specific
ethnicity of patients with lung cancer, and that XPD
Lys751Gln and Asp312Asn may differentially affect individ-
FIGURE 1. Forest plot (random-effects model) of lung cancer risk associated with XPD Lys751Gln genotype for CC versus AA.
Each box represents the odds ratio (OR) point estimate, and its area is proportional to the weight of the study. The diamond
(and broken line) represents the overall summary estimate, with confidence interval (CI) represented by its width. The unbro-
ken vertical line is set at the null value (OR  1.0).
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uals of different ethnic genetic backgrounds for risk of lung
FIGURE 3. Begg’s funnel plot of XPD Lys751Gln gene poly-
morphism and lung cancer risk for CC versus AA.
FIGURE 4. Begg’s funnel plot of XPD Asp312Asn gene
polymorphism and lung cancer risk for AA versus GG.
FIGURE 2. Forest plot (random-effects model) of lung cancer risk associated with XPD Asp312Asn genotype for AA versus GG.
Journal of Thoracic Oncology • Volume 5, Number 9, September 2010 Gene Polymorphism and Lung Cancer Risk
Copyright © 2010 by the International Association for the Study of Lung Cancer 1343
cancer. The different genetic background in different popu-
lations may to some extent explain the different risk estimates
associated with the XPD variant alleles. Prevalence of the
variant XPD alleles and genotypes varies markedly with
ethnicity. The 312A allele frequency was varied from 0.28 to
0.4 in Caucasians,14,18,20,22 whereas it was only 0.067 among
Asians.23 However, this XPD 751C variant was much less
common among Asians than those among Caucasians and
African Americans.20,23 Population stratification is an area of
concern in any complex disease association study because it
can confound the linkage results between a molecular marker
and phenotype.40 The observed ethnic differences may also
be a result of chance because studies with small sample size
are likely to be insufficiently powered to detect a slight effect.
Tobacco smoke contains many known carcinogens and
procarcinogens, such as benzopyrene and nitrosamine. Our
meta-analysis results showed that significantly increased risks
were found to be associated with the XPD Lys751Gln and
Asp312Asn gene polymorphisms and lung cancer risk in
smokers. Only small number of studies examined the asso-
ciation between the XPD gene polymorphism and lung cancer
risk in smokers or nonsmokers; moreover, the p value of Q
test for heterogeneity test was significant. Considering the
limited studies and p value of Q test for heterogeneity test
included in this meta-analysis, our results should be inter-
preted with caution.
Some limitations of this meta-analysis should be ac-
knowledged. First, heterogeneity is a potential problem when
interpreting the results of any meta-analyses. Although we
minimized the likelihood by performing a careful search for
published studies, using strict criteria for study inclusion and
to perform data extraction and data analysis, significant
between-study heterogeneity still existed in almost each com-
parison. The presence of heterogeneity may have resulted
from differences in the selection of controls, age distribution,
prevalent lifestyle factors, and so forth. Although most of the
controls were selected from healthy populations, some stud-
ies had selected controls among friends or family members of
patients with lung cancer or other diseases. Second, only
published studies were included in this meta-analysis. The
presence of publication bias may reflect the fact that nonsig-
nificant or negative findings tend not to be published. Finally,
our results were based on unadjusted estimates. A more
precise analysis should be conducted if individual data were
available, which would allow for the adjustment of other
covariates including age, ethnicity, family history, environ-
mental factors, and lifestyle.41
Despite some limitations, this meta-analysis suggested
that the XPD Lys751Gln and Asp312Asn gene polymor-
phisms were associated with lung cancer risk; the C allele of
XPD Lys751Gln genotype was an increased risk factor for
developing lung cancer among Caucasians and in smokers;
and, the A allele of the XPD 312 genotype was also an
increased risk factor for developing lung cancer among
Asians and in smokers. However, it is necessary to conduct
large clinical trials using standardized unbiased methods,
patients with homogeneous lung cancer and well-matched
controls, with the assessors blinded to the data. Moreover,
gene–gene and gene–environment interactions should also
be considered in the analysis. Taking these factors into
account, such studies may eventually lead to a more compre-
hensive understanding of the association between the XPD
gene polymorphism and lung cancer risk.
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